This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gross, N. D. Articles by Dannenberg, A. J. Search for Related Content PubMed PubMed Citation Articles by Gross, N. D. Articles by Dannenberg, A. J.

Inhibition of Jun NH₂-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma

Authors' Affiliations: ¹ Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon; Departments of ² Surgery (Head and Neck Service) and ³ Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center; and ⁴ Department of Medicine, Weill Medical College of Cornell University, New York, New York

Requests for reprints: Andrew J. Dannenberg, New York Presbyterian-Cornell, 525 East 68th Street, Room F-206, New York, NY 10021. Phone: 212-746-4403; Fax: 212-746-4885; E-mail: ajdannen{at}med.cornell.edu.

Purpose: This study was carried out to investigate whether c-Jun NH₂-terminal kinases (JNK) are potential targets for treating head and neck squamous cell carcinoma (HNSCC).

Experimental Design: JNK activity was first evaluated in 20 paired samples of human HNSCC. The antitumor activity of SP600125, a reversible nonselective ATP-competitive inhibitor of JNKs, was then investigated both in an HNSCC xenograft model and in vitro using immunohistochemistry, immunoblotting, enzyme immunoassay, flow cytometry, and a Matrigel assay of capillary tube formation. Complementary studies were carried out using small interfering RNA to JNK1/2.

Results: JNK activity was increased in human HNSCC compared with normal-appearing epithelium. Treatment of mice bearing HNSCC xenografts with SP600125 resulted in >60% inhibition of tumor growth relative to vehicle-treated animals. Inhibition of tumor growth was associated with significant reductions in both cell proliferation and microvessel density. SP600125 inhibited tumor cell proliferation by causing delays in both the S and G₂-M phases of the cell cycle. Inhibition of angiogenesis seemed to reflect effects on both tumor and endothelial cells. The JNK inhibitor suppressed the production of vascular endothelial growth factor and interleukin-8 by tumor cells and also inhibited endothelial cell proliferation and capillary tube formation. Reduced amounts and phosphorylation of epidermal growth factor receptor were found in tumor cells after treatment with SP600125. Small interfering RNA–mediated suppression of JNK1/2 led to reduced tumor cell proliferation and decreased levels of epidermal growth factor receptor, vascular endothelial growth factor, and interleukin-8.

Conclusions: JNK activity is commonly increased in HNSCC. Our preclinical results provide a rationale for evaluating JNK inhibition as an approach to treating HNSCC.

This article has been cited by other articles:

				N. Tamaki, E. Hatano, K. Taura, M. Tada, Y. Kodama, T. Nitta, K. Iwaisako, S. Seo, A. Nakajima, I. Ikai, et al. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G498 - G505. [Abstract] [Full Text] [PDF]